Navigation Links
Cephalon Gives Notice of Anticipated Fundamental Change to Holders of Its 2.50% Convertible Senior Subordinated Notes due 2014 and 2.00% Convertible Senior Subordinated Notes due 2015
Date:8/22/2011

a wholly-owned subsidiary of Teva Pharmaceutical Industries Ltd. in October 2011 and, in addition, may include statements regarding anticipated scientific progress on its research programs, development of potential pharmaceutical products, interpretation of clinical results, prospects for regulatory approval, manufacturing development and capabilities, market prospects for its products, sales and earnings guidance, and other statements regarding matters that are not historical facts. You may identify some of these forward-looking statements by the use of words in the statements such as "anticipate," "estimate," "expect," "project," "intend," "plan," "believe" or other words and terms of similar meaning. Cephalon's performance and financial results could differ materially from those reflected in these forward-looking statements due to general financial, economic, regulatory and political conditions affecting the biotechnology and pharmaceutical industries as well as more specific risks and uncertainties facing Cephalon such as those set forth in its reports on Form 8-K, 10-Q and 10-K filed with the SEC. Given these risks and uncertainties, any or all of these forward-looking statements may prove to be incorrect. Therefore, you should not rely on any such factors or forward-looking statements. Furthermore, Cephalon does not intend to update publicly any forward-looking statement, except as required by law. The Private Securities Litigation Reform Act of 1995 permits this discussion.Cephalon:Investor Contacts:Media Contacts:Chip Merritt

(610) 738-6376

cmerritt@cephalon.comFritz Bittenbender

Cell: (610) 457-7041

Office: (610) 883-5855

fbittenb@cephalon.comJoseph Marczely

(610) 883-5894

jmarczely@cephalon.comNatalie de Vane

Cell: (610) 999-8756

Office: (610) 727-6536

'/>"/>

SOURCE Cephalon, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Cephalon Receives FDA Approval for Risk Evaluation and Mitigation Strategy for FENTORA and ACTIQ
2. Cephalon Shareholders Approve Acquisition by Teva
3. Valeant Pharmaceuticals Congratulates Teva and Cephalon on Their Transaction
4. Valeant Pharmaceuticals Responds to Cephalon Boards Letter
5. Valeant Pharmaceuticals Adds Corporate Governance Expert Abe Friedman to its Slate of Proposed Cephalon Directors
6. Cephalon Lodges Bidders Statement for A$167 Million Offer for ChemGenex Pharmaceuticals
7. Valeant Pharmaceuticals Files Presentation for Cephalon Stockholders
8. Valeant Pharmaceuticals Proposes to Acquire Cephalon, Inc. for $73 Per Share in Cash
9. Cephalon Launches Recommended Takeover Bid For Australian Biopharmaceutical Company, ChemGenex Pharmaceuticals Limited
10. Cephalon Wins FENTORA Patent Suit Against Watson
11. Cephalon Announces Definitive Agreement to Acquire Gemin X
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Jan. 15, 2014 The Cadence Fitness & Health ... by the Medical Fitness Association, a non-profit organization assisting ... full potential. The Cadence Fitness & Health Center is ... and second in the Chicagoland area. "The ...
(Date:1/15/2014)... , Jan. 15, 2014 Reportlinker.com ... is available in its catalogue: ... Drug Forecast and Market Analysis to 2022 ... PharmaPoint: Atopic Dermatitis - India Drug Forecast ...
(Date:1/15/2014)... 15, 2014 Reportlinker.com announces that ... available in its catalogue: ... for Advanced Drug Delivery Systems -- ... http://www.reportlinker.com/p01941928/Global-Markets-and-Technologies-for-Advanced-Drug-Delivery-Systems----Focus-on-Routes-of-Administration.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_Delivery_Technology ...
Breaking Medicine Technology:Cadence Fitness & Health Center Certified as Medical Fitness Facility 2Cadence Fitness & Health Center Certified as Medical Fitness Facility 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 16
... PITTSBURGH, Sept. 1 invivodata inc., the ... for global clinical research, today announced that the company has been ... privately-held companies in Western Pennsylvania by the Pittsburgh Business Times. ... as one of the most important lists we publish," said Alan ...
... , NATICK, Mass., and BARCELONA, Spain, ... today announced final results from the landmark MADIT-CRT trial, which were ... presented during a Hot Line session at the annual European Society ... To view the Multimedia News Release, go to: http://www.prnewswire.com/mnr/bostonscientific/36500/ ...
Cached Medicine Technology:invivodata Recognized as One of Pittsburgh's Fastest Growing Private Companies 2invivodata Recognized as One of Pittsburgh's Fastest Growing Private Companies 3Video: MADIT-CRT Trial Results Provide Clinical Evidence That Cardiac Resynchronization Therapy Significantly Slows Heart Failure Progression 2Video: MADIT-CRT Trial Results Provide Clinical Evidence That Cardiac Resynchronization Therapy Significantly Slows Heart Failure Progression 3Video: MADIT-CRT Trial Results Provide Clinical Evidence That Cardiac Resynchronization Therapy Significantly Slows Heart Failure Progression 4Video: MADIT-CRT Trial Results Provide Clinical Evidence That Cardiac Resynchronization Therapy Significantly Slows Heart Failure Progression 5
(Date:4/23/2014)... Rochelle, NY, April 23, 2014Men whose testosterone falls below ... and to be overweight and have heart disease and ... to identify testosterone-deficient men for further testing and possible ... of Men,s Health , a peer-reviewed publication from Mary ... on the Journal of Men,s Health website ...
(Date:4/23/2014)... and vegetables are often displayed in the popular ... also plenty of high-sugar foods. A new study ... is portrayed in children,s TV programmes as well ... dietary habits and weight status. , Steingerdur Olafsdottir,s ... in the popular Swedish children,s TV show Bolibompa. ...
(Date:4/23/2014)... and Leisure Time Physical Activity on Mobility Limitation in ... increases the risk of mobility limitation in old age, ... found in a study which followed up 5,200 public ... at the Gerontology Research Center in Finland and the ... is often repetitive, wears the body and lasts for ...
(Date:4/22/2014)... Basketball is a popular high school sport in the ... published study by researchers in the Center for Injury ... first to compare and describe the occurrence and distribution ... the high school athletic training setting among adolescents and ... Journal of Athletic Training , examined data relating to ...
(Date:4/22/2014)... 2014 Researchers at UT Southwestern Medical Center are ... depression . , A team of physician-scientists at ... ghrelin (a hormone with natural anti-depressant properties) works inside ... new treatment for depression in the form of a ... study, published online in April,s issue of Molecular ...
Breaking Medicine News(10 mins):Health News:High-calorie and low-nutrient foods in kids' TV 2Health News:Midlife occupational and leisure-time physical activity limits mobility in old age 2Health News:New study finds 2.5 million basketball injuries to high school athletes in 6 seasons 2Health News:New study finds 2.5 million basketball injuries to high school athletes in 6 seasons 3Health News:Depressed? Researchers identify new anti-depressant mechanisms, therapeutic approaches 2Health News:Depressed? Researchers identify new anti-depressant mechanisms, therapeutic approaches 3
... birds to control a new outbreak of avian flu at ... said Wednesday. ,Laboratory tests confirmed the presence ... in humans, at three farms in Chak Shehzad, where about ... of the Agriculture and Livestock Ministry. ,There were ...
... the state-run super speciality SSKM Hospital in Kolkata was arrested ... a medical test Tuesday night. ,"We have ... of outraging the modesty of this 32-year-old lady during an ... IANS. ,"A complaint was lodged by the woman's ...
... researcher at the Biodesign Institute at Arizona State University has ... stability and functions in comparison with the ones that occurred ... claims to have evolved several new proteins in a fraction ... ,The new findings have led to some surprisingly new ...
... approved Wyeth's oral contraceptive Lybrel, which is designed to ... Lybrel, which contains a lower dose of synthetic ... is taken 365 days a year with no placebo ... active pills taken consecutively, followed by seven placebo pills. ...
... used gene therapy to reverse heart failure in animals. ... strategy had "unique and additive effects" to currently used, ... in the American Heart Association journal Circulation, researchers led ... for Translational Medicine and the George Zallie and Family ...
... Researchers at the University of Warwick have found that sexual ... tasks such as navigating with a map in a ... of sexual orientation and withers all mens minds alike just ... worked with the BBC to collect data from over 198,000 ...
Cached Medicine News:Health News:FDA Approves Wyeth's Oral Contraceptive Lybrel 2Health News:Scientists Use Gene Therapy to Reverse Heart Failure in Animals 2Health News:Scientists Use Gene Therapy to Reverse Heart Failure in Animals 3
... Long Instrument for applications in ... Plus Long Instrument with 150mm ... endoscopic entry device that has ... is used to establish entry ...
... The Autosuture™ Blunt Tip Trocar consists ... handle and a valve body assembly. , ... internal flapper valve and seal to prevent ... withdrawn. The Autosuture™ Blunt Tip Trocar includes ...
... components are supplied sterile. , ,The Step™ ... sterile in 2/3, 5, 7/8, 10 and 12 ... They are used in conjunction with the Step™ ... Expandable Sleeve. The 5, 7/8, 10 and 12 ...
... The Step™ and Mini Step™ device components are ... Step™ Single Use System is supplied sterile in ... packaged in various configurations and combinations. They are ... Access needle and the Step™ radially Expandable Sleeve. ...
Medicine Products: